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Abstract
Background: The 7-valent pneumococcal conjugate vaccine has been introduced in national immunisation 
programmes of most industrialised countries and recently in two African GAVI eligible countries (Rwanda and The 
Gambia). However the long term effects of PCV are still unclear, as beneficial direct and herd immunity effects might be 
countered by serotype replacement.
Method: A dynamic, age-structured, compartmental model of Streptococcus pneumoniae transmission was developed 
to predict the potential impact of PCV7 on the incidence of invasive disease accounting for both herd immunity and 
serotype replacement effects. The model was parameterised using epidemiological data from England and Wales and 
pre and post-vaccination surveillance data from the US.
Results: Model projections showed that serotype replacement plays a crucial role in determining the overall effect of a 
PCV7 vaccination programme and could reduce, negate or outweigh its beneficial impact. However, using the 
estimate of the competition parameter derived from the US post-vaccination experience, an infant vaccination 
programme would prevent 39,000 IPD cases in the 20 years after PCV7 introduction in the UK. Adding a catch-up 
campaign for under 2 or under 5 year olds would provide a further reduction of 1,200 or 3,300 IPD cases respectively, 
mostly in the first few years of the programme.
Conclusions: This analysis suggests that a PCV vaccination programme would eradicate vaccine serotypes from 
circulation. However, the increase in carriage of non-vaccine serotypes, and the consequent increase in invasive 
disease, could reduce, negate or outweigh the benefit. These results are sensitive to changes in the protective effect of 
the vaccine, and, most importantly, to the level of competition between vaccine and non-vaccine types. The 
techniques developed here can be used to assess the introduction of vaccination programmes in developing countries 
and provide the basis for cost-effectiveness analyses.
Background
Despite the considerable burden of disease caused by
Streptococcus pneumoniae infection in developing coun-
tries, the available 7-valent pneumococcal conjugate vac-
cine (PCV7) introduced in 2000 in the US and included in
a number of European countries routine immunisation
schedules [1], has yet to be launched in the majority of
low-income settings where it is most needed [2]. If on one
hand the high price of the vaccine has been a limiting fac-
tor, discussions are also ongoing in regards to the feasibil-
ity of the programme as well as its long term
effectiveness. Though in fact the vaccine has been shown
to be effective against invasive and non invasive disease
[3-8], the current licensed product contains seven sero-
types only (14, 6B, 19F, 23F, 4, 9V, 18C) and it cannot be
expected to provide any protection against carriage or
disease caused by most other serotypes. On the contrary,
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evidence from several countries suggests that serotype
replacement in carriage generates as a consequence of
vaccination [9-12]. An increase in carriage prevalence of
serotypes not contained in the vaccine as well as in dis-
ease has now been reported suggesting that replacement
in carriage may also lead to replacement in disease [13-
16].
While surveillance systems can and should closely
monitor country-specific trends in the post vaccination
era, there is the need to investigate the potential scenarios
that the longer term effects of these interventions might
produce and to evaluate the economic acceptability of
such interventions considering medium to longer term
consequences such as herd immunity and serotype
replacement.
Transmission dynamic models have now been exten-
sively used to describe the dynamics of infectious dis-
eases [17] and to predict the effects of vaccination against
many childhood infections [18-24]. These models are
needed to evaluate the amount of herd immunity that can
be generated by these programs [25]. Also, by describing
the natural history of the infection, they can provide
insights on the magnitude of other indirect effects, such
as serotype replacement, and on the aspects that need to
be considered when evaluating the overall impact of these
mechanisms. Here we use population-based data to
develop, parameterise and apply an age-structured trans-
mission dynamic model [26] and to explore the impact of
different PCV7 vaccination strategies on carriage of vac-
cine- and non-vaccine pneumococcal serotypes (VT and
NVT) and on invasive pneumococcal disease (IPD). This
model differentiates from previous more theoretical work
[27,28] by the inclusion of an age structure, heteroge-
neous mixing and the calculation of IPD rates. An age-
structured model was considered essential to assess the
public health and economic impact of alternative vacci-
nation policies, since the risks of pneumococcal carriage
and disease are highly correlated with age, and vaccina-
tion programs are targeted at specific age groups (routine
vaccination, booster doses, and catch-up campaigns).
Our work is also different from other recent and more
applied models which looked at the effects of infant vac-
cination on the epidemiology of S. pneumoniae infection,
by using pre and post invasive disease surveillance data
from, respectively, Australia and the US [29,30]. Neither
of these two studies, in fact, looked at the impact of vacci-
nation on the ecology of the bacterium and, in particular,
on the possibility that non-vaccine serotypes will replace
serotypes eliminated by the vaccine. This phenomenon is
currently being observed in England and Wales post vac-
cine introduction http://www.hpa.org.uk and it is having
major implications for the overall impact of the pro-
gramme.
The model presented here generates projections for
England and Wales and evaluates the policies that were
under consideration at the Department of Health for the
UK at the time of introduction of PCV7. However, future
changes to the vaccine formulations and/or schedule can
be considered with the current model and it can also be
adapted to look at other countries programs. Mathemati-
cal models can provide insights on the overall impacts
produced by alternative public health interventions and
should be used by policy makers as an additional tool to
inform their decision.
Methods
Data
The following three distinctive datasets were used to
parameterise the model:
• pneumococcal carriage prevalence data from England
and Wales [31] to estimate the pre-vaccination steady
state force of infection
• the national enhanced surveillance of IPD in England
and Wales [32] to derive the case:carrier ratio (i.e. the
proportion of infection that progress into a disease state)
• the Active Bacterial Core Surveillance data (ABC)
[33] which, by providing unique at the time of the analysis
pre and post vaccination data allowed the estimation of
key model parameters such as degree and duration of
vaccine protection and competition between vaccine and
non-vaccine serotypes.
In the following a brief description of the three datasets
is given.
England &Wales longitudinal carriage data
A longitudinal study was carried out by collecting
nasopharyngeal swabs every month from 489 individuals
including 121 pre-school children (<3 yrs.) for a period of
10 months, from October 2001 to July 2002 in England
and Wales [31,34]. Swabs were cultured for pneumococci
according to the WHO guidelines [35]. The number of
positive pneumococcal swabs was 932 among the 3,753
swabs taken, (25%), and 34 pneumococcal serotypes were
identified (Figure 1). Among these serotypes, 6A, 6B, 14,
19F and 23F were the major serotypes identified from
positive swabs (75% in children and 52% in adults). The
serotypes included in PCV7 and 6A were identified from
80% of positive swabs from children aged under 5 and
67% of those from subjects aged 5 and older.
England &Wales national surveillance of invasive 
pneumococcal disease
The annual number of IPD cases was estimated as the
average of the overall number of cases that were reported
to the reconciled enhanced surveillance system of inva-
sive pneumococcal disease for England & Wales [36,37]
and over the 2003/04 and 2004/2005 epidemiological
years. This surveillance system is currently the largestMelegaro et al. BMC Infectious Diseases 2010, 10:90
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national data source on invasive disease caused by S.
pneumoniae infection and on the isolated serotypes (Fig-
ure 2). The average annual number of IPD cases during
the pre-vaccination period (between 2003/04 and 2004/
05) in England and Wales was 6,184.
Active Bacterial Core surveillance of invasive pneumococcal 
disease
The Active Bacterial Core Surveillance (ABCs) is an
active laboratory and population-based surveillance sys-
tem for invasive bacterial pathogens of public health
importance. From the ABCs system, IPD cases were iden-
tified from 8 counties in the US (California, Connecticut,
Georgia, Maryland, Minnesota, New York, Oregon and
Tennessee). The total population is estimated at
18,041,585 (2004 post-censual estimates) and the total
number of IPD cases was 22,365 for the period 1998-2004
[33]. As the PCV7 was introduced in mid 2000, the aver-
age number of IPD cases during 1998 and 1999 was used
as the pre-vaccination figure and the effects of PCV7 are
presented in Figure 3.
Model
Population
The model consists of 100 cohorts of individuals (0, 1, 2,
3,..., 99) each corresponding to one year of age and each
of equal size (nc = 0.01), with a total stable population (i.e.
births equal deaths) which adds up to 1 [26]. Individuals
are born into age cohort 0 at the start of the year and live
to the age of 99 years, at which point they die. Ageing is
thus modelled at the end of each year, with individuals in
age group i moving up to become age group i+1. Each age
cohort goes through the transmission cycles according to
the infection process outlined in the following paragraph.
Structure
A compartmental transmission dynamic model is devel-
oped to examine the effects of PCV7 on VT and NVT
carriage prevalence and, ultimately, on the overall inci-
dence of IPD. Serotypes 4, 6B, 9V, 14, 18C, 19F, 23F as
well as serotype 6A are all included in the VT group.
Though 6A is not explicitly included in PCV7, carriage of
this serotype is assimilated to the VT one as PCV7 was
shown to elicit strong opsonic capacity against serotype
6A [38] and a significant reduction of 6A carriage was
observed following vaccination [10,39,40]. In the model,
carriage of any of the remaining pneumococcal serotypes
is considered a NVT carriage episode.
The model consists of a set of ordinary differential
equations, which describes the transmission and clear-
ance of carriage with and without vaccination. The model
structure is shown in Figure 4 and details of the equations
are provided in Appendix 1. A Susceptible-Infected-Sus-
ceptible (SIS) type model is chosen (i.e. no immunity after
infection) and individuals can get co-infected with one
serotype from the VT group and one from the NVT
group. Thus, a model that did not consider vaccination
would require four compartments: S, non-carriers; V, car-
riers of VT pneumococci; N, carriers of NVT pneumo-
cocci; B, carriers of both VT and NVT pneumococci. To
enable consideration of vaccines that provide partial pro-
tection against carriage, the model has four additional
compartments for individuals that have a degree (i.e. vac-
cine efficacy against VT carriage acquisition) of vaccine-
induced protection (Sv, Vv, Nv, Bv).
Infection Uninfected, unprotected individuals (S)
become infected according to the age-specific force of
infection of vaccine type (λVi) and non-vaccine type (λNi)
pneumococci. Individuals carrying VT become co-colo-
Figure 1 Serotype distribution of pneumococcal carriage, Eng-
land and Wales. Serotype distribution of pneumococcal carriage from 
a longitudinal study carried out by collecting nasopharyngeal swabs 
every month from 489 individuals including 121 pre-school children 
(<3 yrs.) for a period of 10 months, from October 2001 to July 2002 in 
England & Wales [31,34]. Black bars are serotypes included in PCV7 and 
white bars are serotypes not included in PCV7. One serotype, 6A, is in-
cluded in the vaccine serotype group due to evidence of cross-protec-
tion.
Figure 2 Serotype distribution of invasive pneumococcal disease 
cases, England and Wales. Serotype distribution of invasive pneumo-
coccal disease (IPD) isolates reported to the national enhanced surveil-
lance system in England and Wales. IPD cases in the vaccine serotype 
group are shown in black bars and IPD cases in the non-vaccine sero-
type group in white bars. Data shown refer to the years 2004 and 2005.Melegaro et al. BMC Infectious Diseases 2010, 10:90
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nised at a rate cNλNi where cN is the relative susceptibility
of an individual colonised with VT to acquiring NVT
compared with an uncolonised individual. Similarly NVT
carriers become co-infected at a rate cVλVi. Once
infected, individuals can recover from carriage and go
back to a susceptible state (VTS or NTS) or, if they were
co-colonised, to carriage of a unique type (BTV or BTN).
This happens at an age-dependent rate ri which is the
same whether or not the individual was in the colonised
state (V or N) or in the co-colonised state (B).
Vaccination Following vaccination, all vaccinated indi-
viduals move into the equivalent vaccine-protected com-
partment according to their carriage status, and gain
partial protection against VT acquisition. The force of
infection of VT pneumococci, among vaccine-protected
individuals, is reduced by a factor (1-γi) where γi is the
degree of protection. The force of infection for NVT
among vaccine-protected individuals is the same as
among unprotected individuals. Vaccine-protected indi-
viduals may lose their protection and go back to the
equivalent unprotected compartment at a waning rate w
(= 1/δ, where δ is the average duration of protection) that
is constant throughout all ages and across all compart-
ments. Vaccination is assumed not to affect infectious-
ness: vaccinated VT carriers are assumed to be as
infectious as unvaccinated VT carriers.
Vaccination programs in the model are implemented as
discrete events, rather than as a continuous process at
some constant rate: in a routine vaccination program all
infants in a cohort are assumed to be vaccinated at the
same time according to the vaccination schedule; and in a
catch-up campaign individuals in the targeted age group
are assumed to be vaccinated simultaneously.
Disease We assume that the risk of disease occurs at the
time of carriage acquisition. The proportions of those
infected who develop IPD, Case: Carrier ratios, depend
on their age and the infecting serotype (VT or NVT).
Parameterisation
Recovery rates
The average duration of carriage was estimated using a
previously developed modelling framework [41,42] and
considering the following age classes: 0-1, 2-4, 5-17 and
18+. Carriage episode was found to be significantly lon-
ger in young children (72 days in the 0-1 year of age), and
then steadily decreasing with 28 days in the 2-4 years of
age, 18 in the 5-17 years and 17 days in the 18+. Age-
dependent recovery rates (1/average duration of carriage)
were assumed to be the same for VT and NVT (rVi = rNi)
Figure 3 Pre and post PCV7 vaccination IPD data in the US. Age distribution of IPD cases belonging to the vaccine serotype group (+6A) and non-
vaccine serotype group (-- 6A) in 8 counties included in the Active Bacterial Core Surveillance data in the US between 1998 and 2004.Melegaro et al. BMC Infectious Diseases 2010, 10:90
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[41,43], and also for vaccinated and unvaccinated individ-
uals (Table 1).
Forces of infection
The forces of infection for VT and NVT were age- and
time-dependent, varying as a function of the number of
vaccinated and unvaccinated carriers in each age class j
and the rate of effective contacts between individuals in
the age class i and those in age class j (βij), as follows:
The derivation of the transmission rates βij and the
underlying assumptions on the mixing patterns adopted
in the model are described in Appendix 2 and follow the
techniques originally developed for sexually-transmitted
infections [44]. In brief, the contact patterns within and
between age groups ranges from fully assortative to pro-
portionate, governed by a single parameter, ε (0≤ε≤1) (ε =
0 proportionate; ε = 1 assortative), which is estimated by
lb Vi V ij j j j j
j
t V t Vv t B t Bv t () () () () () , =⋅ + + + () ∑
lb Ni N ij j j j j
j
t N t Nv t B t Bv t () () () () (). , =⋅ + + + () ∑
Figure 4 Model structure. Flow diagram illustrating the structure of 
the dynamic model used to assess pneumococcal vaccination. The fol-
lowing states are included: S, unvaccinated susceptible; Sv, susceptible 
vaccinated; V, unvaccinated carriers of pneumococcal serotypes con-
tained in PCV7 or serotype 6A (vaccine serotype group, VT); Vv, vacci-
nated carriers of pneumococcal serotypes contained in PCV7 or 
serotype 6A; N, unvaccinated carriers of pneumococcal serotypes not 
contained in PCV7 (non-vaccine serotype group, NVT); Nv, vaccinated 
carriers of pneumococcal serotypes not contained in PCV7; i, age; t, 
time; λ, force of infection; γ, degree of protection against acquisition of 
VT carriage; ν, vaccine coverage; c, competition parameters; ω, waning 
rate of vaccine induced protection.
Table 1: Model parameters
Base case Range Source
Duration of carriage (days): [41,42]
0-1 y 72
2-4 y 28
5-17 y 18
18+ y 17
cV 0.5 0-1 [41]
cN 0.85* 0.5-1 *Fitted to US data
ε, mixing pattern 0.87* 0.7-0.95 *Fitted to US data
1/ω, average duration of 
protection
8.3 y* 5-20 y# *Fitted to US data
#95% CI estimated
γ, degree of protection 0.756* 69-84%#^ *Fitted to US data
#95% CI estimated
^duration and degree of protection are correlated; i.e. short duration is paired with high protection
Transmission parameters of pneumococcal carriage for the base case and ranges used in the sensitivity analyses.Melegaro et al. BMC Infectious Diseases 2010, 10:90
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fitting model projections to the US post vaccination sur-
veillance data as described below.
Mixing and Competition parameters
The introduction of PCV7 for routine use in children
aged <5 years in the United States yields valuable infor-
mation about the impact of vaccination at a population
level. We used national surveillance data on the number
o f  c a s e s  o f  i n v a s i v e  d i s e a s e  c a u s e d  b y  V T  a n d  N V T
before and in the four years after the vaccine introduction
[45] to estimate mixing pattern and competition parame-
ters. In particular, the impact on VT carriage among the
unvaccinated age groups provided information on the
mixing patterns in the population (ε). The speed and
extent of the increase in NVT disease provided the esti-
mate of cN  (how much VT carriage protects against
acquisition of NVT). As there is little information in this
data set on cV, we used the value, cV = 0.5, as a baseline
value, and analysed the sensitivity using the values of 0
and 1. We optimised ε and cN by fitting to the incidence of
IPD in each age group from the US data by minimizing
the Poisson deviance. The reported annual coverage level
for 1+ doses in children between 19 and 35 months in
2003 of 86% (Dr Cynthia Whitney, personal communica-
tion) was assumed as the baseline annual vaccine cover-
age of routine vaccination from 2001 onward.
Vaccination coverage in the first year of the program was
set at 43% for 0 (routine) and 1 (catch-up) year olds as the
vaccine was introduced around the middle of the year
(July 2000). As the vaccine coverage levels varied each
year, the coverage assumed in the model was varied as
well, from 80% to 90% with an increment of 2% for the
sensitivity analysis.
The risk of disease given pneumococcal infection
The age-specific proportions of VT and NVT pneumo-
coccal infections that lead to IPD (case: carrier ratio)
were estimated by fitting a model to the age-specific inci-
dence of these diseases attributable to pneumococci as
reported from the national enhanced surveillance of
pneumococcal disease in the pre-vaccination years [46].
A total of eighteen case: carrier ratios for VT and NVT
were estimated for nine age groups, <2 months, 2-11
months, 1-4, 5-14, 15-24, 25-44, 45-64, 65-74, 75+ years.
Vaccine associated parameters
We assume that all individuals who received PCV7 move
to the vaccine protected group. The average duration and
degree of vaccine-induced protection were estimated by
fitting the model to the ABCs data from the pre- and
post- vaccination US experience. The sensitivity of the
model results to these parameter estimates was assessed.
Modelling PCV7 vaccination
The alternative vaccination strategies investigated here
are the ones that were relevant for the UK routine immu-
nisation schedule:
 Strategy 1: routine vaccination at 2 and 4 months of
age, plus a booster dose at 12 m;
 Strategy 2: Strategy 1 plus catch-up campaign target-
ing all those under the age of 24 m;
 Strategy 3: Strategy 1 plus catch-up campaign target-
ing all those under the age of 60 m.
For each vaccination strategy the model predicted the
number of cases of IPD caused by VT and NVT in each
age group over time. The coverage of routine and catch-
up vaccinations for PCV7 in the UK was assumed to be
the same as for the meningococcal serogroup C conjugate
vaccine pre-school catch-up (89% for 0 year olds, 84% for
1 year olds, and 76% for the rest) [47]. Catch-up cam-
paigns were implemented at the same time as the routine
vaccination was introduced.
Model analysis
There were three stages to the analysis. First, a steady
state pre-vaccination model estimated age-stratified val-
ues for the forces of infection and case:carrier ratios for
VT and NVT. Second, a dynamic post-vaccination model
estimated key vaccine parameters, interaction between
VT and NVT and the level of assortativeness of mixing
pattern from US surveillance data. Third, the dynamic
model was used to assess the impact of alternative vacci-
nation strategies in England and Wales.
The pre-vaccination model was programmed in Excel
to estimate forces of infection for VT and NVT and for
the following age groups: 0-1, 2-4, 5-9, 10-19, 20-39 and
40-99 using the carriage prevalence data available for
England and Wales and a given value for the competition
parameter (cN). The fully assortative and fully propor-
tionate mixing matrices between the six age-groups were
also generated and later used as two extremes in the
transmission model. Age-specific case:carrier ratios were
then derived fitting the model to the age distribution of
IPD cases caused by, respectively, vaccine and non-vac-
cine serotypes in the pre-vaccination era. The procedure,
which required the minimisation of a Poisson deviance
using the SOLVER in Excel, was run for both England and
Wales and the US to calculate the risk of developing dis-
ease when colonised.
The transmission dynamic model was programmed in
Berkeley Madonna (R. I. Macey & G. F. Oster, UC Berke-
ley, CA, USA) and fitted to the pre- and post- vaccination
IPD data from the US to estimate degree and duration of
protection of the vaccine against invasive disease, and the
mixing parameter (ε) for different values of the competi-
tion parameter (cN). The forces of infection, case:carrier
ratios and extreme mixing matrices were updated for
each value of cN. The estimate of cN was derived by find-
ing the value that minimised the deviance.
Once the parameters were generated, the epidemiologi-
cal model was used to assess the impact of alternativeMelegaro et al. BMC Infectious Diseases 2010, 10:90
http://www.biomedcentral.com/1471-2334/10/90
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vaccination strategies in England and Wales. The system
was solved using the Euler method to integrate ordinary
differential equations with fixed time steps of 0.001 years.
The model simulated 50 years (five years pre-vaccination
and 45 years after vaccination).
Results
Model calibration
Graphical comparison between the observed and pre-
dicted VT and NVT IPD cases by age group from 1998 to
2004 in the 8 counties covered by the Active Bacterial
Core Surveillance is presented in Figure 5. The baseline
value of the PCV7 coverage with 1+ doses was assumed
to be 86%. The sensitivity of estimates of the degree of
vaccine protection and duration of protection to the
assumed PCV7 coverage was investigated. Increasing the
vaccine coverage assumed may account for some protec-
tion derived by individuals who were only partially vacci-
nated; reducing the vaccine coverage assumed is
equivalent to reducing the take of the vaccine to less than
100%. Parameter estimates are presented in Table 2
according to six vaccine coverage values from 80% to 90%
and show that increases in the coverage level produced
some reduction in the degree and duration of protection
as expected. However, for coverage levels within this
range, the estimates of the competition and mixing
parameters were not sensitive to the assumed vaccination
coverage. These results suggest that individuals who were
carrying VT were partly protected against NVT acquisi-
tion (cN = 85%, 15% protection), and that population mix-
ing was closer to assortative than proportionate (ε = 0.87)
in line with a recent European contact study [48]. The
contour plot presented in Figure 6 describes the 95% con-
fidence area of the degree and duration of the vaccine
protection while the mixing and competition parameter
were fixed (respectively 0.87 and 0.85).
Model projections with vaccination
Seven pairs of the degree and duration of PCV7 vaccine
protection were chosen within the 95% confidence area
(including the best fitted pair with the baseline US PCV7
coverage) and showed that the UK transmission model
predictions of IPD changes are insensitive to the assump-
tions. The fitting results indicated that the higher the
degree is the shorter the duration of protection. The
baseline parameters used for the following simulations of
England and Wales predictions are the ones estimated
when fixing the coverage level to 86% (Table 1). Age-spe-
cific case:carrier ratios that are used for the UK predic-
tions are shown in Table 3.
In the long term, the model predicted that all three
strategies had a similar impact and eliminated transmis-
sion of VT. Strategy 3, which has the largest catch-up, has
the most rapid impact on carriage and IPD, while Strat-
egy 1 with no catch-up was the slowest (Figure 7). The
model results presented in Figure 7 also showed an
increase in the incidence of NVT carriage and IPD after
the introduction of vaccination. The extent of this
replacement of VT by NVT is governed by the reduction
in VT.
In the long term, the model predicts a 63% reduction of
all IPD cases in children aged less than 5 years old and
35% reduction in the rest of the population, which
amounts to the prevention of 2,300 cases of IPD annually
after 20 years of the PCV7 introduction with all three
vaccine programme strategies. Following the results for
the impact on carriage, Strategy 1 is the least effective in
terms of disease prevented. The routine vaccination and
booster for one year old (Strategy 1) reduces 6000 IPD
cases within the first five years of the programme, and an
additional catch-up for children up to 23 months of age
(Strategy 2) prevents extra 1,200 IPD cases. Extending the
catch-up to age 59 month (Strategy 3) prevents further
3,300 IPD cases. The impact of vaccination on the long
term incidence of VT and NVT disease by age group and
vaccine programme strategies is illustrated in Figure 8.
Sensitivity analysis
If the vaccine was less protective than assumed here, (i.e.
lower duration or degree of protection), the program
achieved lower coverage, or the population was less
assortative, then transmission of vaccine types may not
be eliminated. Extensive sensitivity analysis was con-
ducted and the results are presented in Table 4. However,
three main conclusions were drawn. Firstly, a reduction
in the duration and/or degree of protection would pre-
vent elimination of VT. However, increasing the values of
these parameters (90% degree or 20 years) would not pro-
vide much further reduction in disease. Secondly, an
increase in the value of the competition parameter cN
(lower protection from VT carriage) would result in
lower replacement of VT by NVT after PCV7 introduc-
tion and thus in a small number of IPD cases while a
lower competition parameter (i.e. higher protection from
VT carriage) would result in more IPD cases than in the
pre-vaccination period. Thirdly, lower values of ε (less
assortative mixing pattern) would facilitate and hasten
elimination of VT transmission with more IPD case
reductions. On the contrary, higher values of ε would
result in VT continuing to be carried due to less herd
immunity effects of the vaccine.
Discussion
The transmission model of S. pneumoniae infection pre-
sented in this paper enables investigation of the potential
effects of infant PCV7 vaccination. It builds on previous
S. pneumoniae models [27,28] and, by including age-Melegaro et al. BMC Infectious Diseases 2010, 10:90
http://www.biomedcentral.com/1471-2334/10/90
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Figure 5 IPD cases: model projections vs. observed data. Observed (histograms) and fitted (filled squares and circles with lines) vaccine serotype 
group (graphs on the left) and non-vaccine serotype group (graphs on the right) IPD cases by age group in 8 counties of USA where the Active Bac-
terial Core Surveillance data collected the serotyped IPD data between 1998 and 2004.Melegaro et al. BMC Infectious Diseases 2010, 10:90
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structure, allows investigation of the impact of vaccina-
tion on the age-specific incidence of invasive disease.
Simulation results indicated that all of the vaccination
strategies considered in this paper were sufficient to elim-
inate VT transmission in England and Wales with base
case values for vaccination coverage and other parame-
ters. Although the model predicts some replacement of
VT with NVT, the annual total of IPD cases was reduced
from 6,184 to 3,765 (38% reduction) in the long-term (20
years after the PCV7 introduction) and reduction of
39,000 IPD cases accumulated over the period. Catch-up
campaigns for children aged under 2 and 5 prevent addi-
tional 1,600 and 4,100 IPD cases respectively compared
to routine vaccination alone during the first twenty years
of the PCV7 program (1,200 and 3,300 cases reduction in
the first five years). However, this conclusion is sensitive
to vaccine and other model parameters. Small reductions
in vaccine coverage, in the duration or degree of protec-
tion, from their base case values are sufficient to prevent
elimination of VT being achieved. We cannot therefore
exclude the possibility that PCV7 vaccination fails to
eliminate VT transmission in the UK. On the other hand,
NVT dynamics post vaccination are extremely sensitive
to the level of competition between VT and NVT, and the
model predicted an overall increase of the number of IPD
cases pre to post vaccination if the level of protection of
VT from NVT acquisition were almost complete.
The competition parameter, cV (the relative susceptibil-
ity of NVT carriers, compared with uncolonised individ-
uals, to acquiring VT carriage), was assumed to be 50%
since there is little information from post-vaccination
surveillance on the protective effect of NVT carriage on
VT acquisition. Sensitivity analysis suggested that the
reduction in annual IPD cases after 10 years of PCV7
introduction is not sensitive to this parameter, with a
maximum difference of 1% between scenarios (cV = 0 or =
100%). On the other hand, the degree of serotype replace-
ment is sensitive to cN (the relative susceptibility of VT
carriers, compared with uncolonised individuals, to
acquiring NVT carriage), which was estimated by fitting
to the US post vaccination surveillance data. The sensitiv-
ity analysis indicated that the lower this value, the more
replacement of VT by NVT will occur after the introduc-
tion of PCV7 in the community. Based on the UK surveil-
lance after the PCV7 introduction, the replacement
appears greater than the replacement in the US http://
www.hpa.org.uk and the cause of this difference is cur-
rently being investigated. Potential contributing factors
include differences in secular trends in prevalence and
antimicrobial sensitivity of specific serotypes at the time
of introduction [49], differences in sensitivity of the
respective surveillance systems, or differences in clinical
practice post PCV introduction.
The mechanism of competition incorporated in the
model may influence the projected outcomes [50]. Here,
the mechanism assumed was of a reduction of the acqui-
sition rate of other serotypes when already colonised.
Figure 6 Estimated degree and duration of protection of the vac-
cine. Contour plane of Poisson deviance calculated from fitting the de-
gree and duration of PCV7 protection with the mixing parameter (ε) 
and competition parameter cN fixed to be respectively 0.87 and 0.85.
Table 2: Best fitted model parameters estimates
US vaccine 
coverage
cN Degree Epsilon Waning Duration of 
PCV7 
protection
Deviance
80% 0.86 0.85 0.88 0.12 8.5 381.09
82% 0.85 0.82 0.88 0.12 8.5 381.16
84% 0.86 0.79 0.88 0.12 8.3 382.16
86% 0.85 0.76 0.87 0.12 8.3 383.12
88% 0.85 0.73 0.87 0.12 8.0 384.48
90% 0.85 0.70 0.86 0.13 7.7 386.29
Best fitted results of cN (competition parameter), epsilon (mixing parameter), waning (1/duration of vaccine protection), degree of vaccine 
protection, and Poisson deviance from the optimization according to a 1+ dose of US PCV7 coverageMelegaro et al. BMC Infectious Diseases 2010, 10:90
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This mechanism is supported by a recent Danish longitu-
dinal study of pneumococcal infection [51], which pre-
ferred it to a mechanism of competition through an
increase in the clearance rate for co-colonised individu-
als. Our exploration of alternative hypotheses for compe-
tition is limited by a lack of co-colonisation data. Clearly,
more work is needed in this area and laboratory tech-
niques that enable detection of carriage of multiple sero-
types will facilitate studies of the interactions between
different pneumococcal serotypes.
The mixing pattern determines herd immunity effects
of PCV7 vaccination among the unvaccinated age groups.
From the impact observed in the US experience, we esti-
mated that the mixing between individuals is more assor-
tative than proportionate. Thus, similarly to other
infections [52], contacts with others in the same age
group play an important role in the transmission of pneu-
mococcal carriage. Population mixing patterns are influ-
ential parameters in transmission models. True mixing
patterns are unknown, and model parameters are often
estimated from the pre-vaccination epidemiology after
making arbitrary assumptions about the structure of con-
tacts [17]. Here, we use post vaccination herd immunity
effects to inform the level of assortativeness of mixing.
Alternative approaches to measure age-specific contact
patterns directly through diary-based methods are cur-
rently being explored using recently collected contact
pattern data [53-56].
The relationship between acquisition of carriage and
onset of invasive and non-invasive disease is not well
understood. Here we assume that the risk of pneumococ-
cal disease occurs at the time of acquisition of carriage,
with age- and type-specific proportions developing IPD.
An alternative assumption is that this risk is spread over
the entire duration of carriage. We do not envisage that
adopting this latter mechanism would markedly affect
our results, especially as we have assumed that the dura-
tion of carriage is the same for both vaccine and non-vac-
cine types.
Table 3: Case:Carrier ratios in the UK
Age group (yrs) VT NVT NVT/VT
0 0.00018 0.00033 1.85
1-4 0.00005 0.00005 0.90
5-14 0.00001 0.00001 1.77
15-24 0.00001 0.00002 2.48
25-44 0.00002 0.00007 3.62
45-64 0.00006 0.00017 2.81
65-74 0.00012 0.00029 2.30
75+ 0.00039 0.00064 1.67
Age-specific Case:Carrier ratios for vaccine and non-vaccine serotypes by age groups in the UK
Figure 7 Model projections for England and Wales. Estimated an-
nual number of vaccine serotype group and non-vaccine serotype 
group IPD cases before (Year 0) and after the introduction of PCV7 
(Year 1) using three different vaccination strategies in England and 
Wales.
Figure 8 Estimated number of IPD cases 20 years post vaccina-
tion and by age. Predicted results on the annual number (vaccine (VT) 
and non-vaccine (NVT) serotype groups) of IPD cases pre-vaccination 
vs post VT elimination 20 years after the PCV7 introduction by age 
group in England and Wales.Melegaro et al. BMC Infectious Diseases 2010, 10:90
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One critical aspect of the current work is that the
model categorises pneumococcal serotypes as either vac-
cine-type (including 6A) or non-vaccine type and
assumes that the characteristics are homogeneous within
each of these two categories. Firstly, the inclusion of sero-
type 6A in the vaccine group was implemented due to
existing evidence that the 7-valent pneumococcal conju-
gate vaccine induces cross-protection against 6A [14,57].
However, the newly identified serotypes 6C and 6D
[58,59], which do not benefit from cross protection
[58,60-62] should be excluded from the vaccine group in
future modelling work. Secondly, there is considerable
heterogeneity between individual serotypes in, for exam-
ple, their transmissibility, duration of infection, ability to
co-colonise, ability to prevent co-colonization with other
serotypes, and potential to cause disease [63-65]. All
these factors may influence the response of individual
serotypes and the pneumococcal population as a whole to
the introduction of infant PCV7 vaccination. Studying
these effects would require an individual-based model in
order to incorporate many circulating serotypes. Within
such a framework it would also be possible to begin to
investigate the impact of acquired immunity on pneumo-
coccal transmission by incorporating a mechanism for
generating type-specific and/or type-independent immu-
nity [66-69].
The impact of pneumococcal vaccination on non-inva-
sive diseases such as Acute Otitis Media (AOM) and
Community Acquired Pneumonia (CAP) is not consid-
ered in this paper although some level of protection has
been reported against these conditions in both developed
[4,70] and developing countries [5,71]. Although an indi-
Table 4: Sensitivity analysis
VT IPD NVT IPD Total
Baseline 0 3765 3765
V, vaccine coverage 0.89
0.5 757 3594 4351
0.95 0 3765 3765
1/w, Duration of 
vaccine protection
8.3 years
5 Years 788 3570 4358
20 Years 0 3765 3765
Degree 0.76
0.3 1599 3338 4937
0.9 0 3765 3765
cV 0.5
0 0 3836 3836
1 2 3710 3712
cN 0.85
0 0 9533 9533
1 0 2921 2921
ε0 . 8 8
0 0 3765 3765
0.95 438 3702 4140
Impact of alternative parameter values on the total number of cases of invasive pneumococcal disease (all ages) caused by vaccine and non-
vaccine serotypes (VT and NVT respectively) and predicted by the model in the 20 years following PCV7 introduction under Strategy 1 in 
England and Wales. Base case parameter values are reported in bold.Melegaro et al. BMC Infectious Diseases 2010, 10:90
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vidual case of non-invasive pneumococcal disease
(NIPD) is generally less severe than IPD, the economic
cost of NIPD is higher than that of IPD due to the much
greater number of cases in the community. Also, CAP is
one of the leading causes of childhood mortality in devel-
oping countries, and hence, understanding the impact of
pneumococcal vaccine on NIPDs is essential to estimate
the overall cost-effectiveness of the program in these set-
tings [72]. The impact of PCV7 vaccination programs on
the incidence of pneumococcal AOM and CAP or even
on the prevalence of carriage in the general population is
currently not well documented. Whilst the capacity of
different serotypes to cause AOM is expected to be simi-
lar, there are large differences in their risk of causing IPD:
some NVT serotypes are very unlikely to cause IPD. The
change in prevalence of NVT serotypes that commonly
cause IPD can be inferred from the IPD data, but the
change in prevalence of NVT serotypes that rarely cause
IPD is not observed. The impact on NIPD may not be in
l i n e  w i t h  t h e  e f f e c t  o n  I P D .  P a r a m e t e r i s i n g  m o d e l s  t o
investigate the effect of the vaccine on AOM or CAP in
the community requires more knowledge of the impact of
vaccination programs on carriage and NIPD.
The outputs of any model are limited by the validity of
the model assumptions and accuracy of the parameter
estimates. In this study, considerable attention was paid
to estimating appropriate parameter values and to assess-
ing the sensitivity of the results to these values. Data from
the longitudinal study in UK families were used to derive
the initial prevalence of carriage, recovery rates and the
forces of infection. Surveillance data on IPD cases pre-
and post- PCV7 introduction in the US were used to esti-
mate vaccine parameters, mixing patterns and to infer the
degree of competition between VT and NVT. Moreover,
the model developed here may also be useful for other
countries considering the introduction of the pneumo-
coccal conjugate vaccine and to estimate effects of alter-
native vaccine strategies. In future, these models will be
improved by refining parameter estimates using the
observed effects of the UK programme. The UK experi-
ence with the Hib and MenC vaccines [73-75] showed
that the post-vaccine era may be far from straightforward
and that continued monitoring the duration of vaccine
protection and the effects of vaccination on carriage may
be critical to the success of the pneumococcal conjugate
vaccine program.
Conclusion
The effect of PCV7 introduction on the burden of IPD is
assessed using an age structured dynamic model which
was parameterised with UK and US data. Model projec-
tions show the importance of considering the existence of
competition between serotypes contained and not con-
tained in the vaccine formulation in order to being able to
realistically predict possible scenarios. The current model
will be extended to incorporate non invasive pneumococ-
cal disease and will form the basis for cost-effectiveness
analysis for alternative vaccination programmes, espe-
cially in developing countries where the burden of pneu-
mococcal disease is extremely high and the financial
resources are limited.
Appendices
A.1. Dynamic model structure in equations
Where i is the age group, νi represents the vaccine cover-
age in age group i, πi(t) is a function, describing the vacci-
nation program in cohort i to occur at certain time as
scheduled, rVi  and rNi are, respectively, the proportion
that recover from VT and NVT infection, ω is the rate of
waning of vaccine-induced protection, cN (cV) represent
the relative susceptibility of VT (NVT) carriers, com-
pared with uncolonised individuals, to acquiring NVT
(VT) carriage (i.e. competition parameters), γ is the vac-
cine efficacy against VT carriage, λVi(t) and λNi(t) repre-
sent the age-specific force of infection for, respectively,
VT and NVT pneumococci at time t.
A.2. Mixing pattern
Given values of the pneumococcal transmission parame-
ters (in particular the competition parameters cV and cN),
the effective transmission coefficients (βVij and βNij) were
calculated by fitting a model to the number of VT and
NVT carriers in each age group at steady state (Figure 9).
Matrices for VT and NVT were calculated assuming fully
assortative (βa) and proportionate (βp) mixing between
the six age groups. A parameter ε, the assortativeness of
mixing, is introduced to define the weight that is given to
each of these matrices [44]:
Figure 9 Observed and estimated prevalence of Streptococcus 
pneumoniae carriage.Melegaro et al. BMC Infectious Diseases 2010, 10:90
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Hence, if ε = 1, then full weight is given to the fully
assortative matrices and mixing patterns is totally assor-
tative whereas if ε = 0 full weight is given to the propor-
tionate matrix. A value of ε is estimated when fitting to
the pre and post vaccination disease incidence data for
the US.
Observed and fitted prevalence of carriage of pneumo-
coccal vaccine and non-vaccine serotypes by age group in
England and Wales are presented in Figure 9. Pneumo-
coccal carriage data were collected as part of a longitudi-
nal pneumococcal family study in the UK that ran from
October 2001 to July 2002 [31].
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